CoChat

Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset

Open access
Chan, M K, Krebs, M-O, Cox, D, Guest, P C, Yolken, R H, Rahmoune, H, Rothermundt, M, Steiner, J, Leweke, F M, van Beveren, N J M, Niebuhr, D W, Weber, N S, Cowan, D N, Suarez-Pinilla, P, Crespo-Facorro, B, Mam-Lam-Fook, C, Bourgin, J, Wenstrup, R J, Kaldate, R R, Cooper, J D, Bahn, S · 2015 · Translational Psychiatry
Cited by 155

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Recent research efforts have progressively shifted towards preventative psychiatry and prognostic identification of individuals before disease onset. We describe the development of a serum biomarker test for the identification of individuals at risk of developing schizophrenia based on multiplex immunoassay profiling analysis of 957 serum samples. First, we conducted a meta-analysis of five independent cohorts of 127 first-onset drug-naive schizophrenia patients and 204 controls. Using least absolute shrinkage and selection operator regression, we identified an optimal panel of 26 biomarkers that best discriminated patients and controls. Next, we successfully validated this biomarker panel using two independent validation cohorts of 93 patients and 88 controls, which yielded an area under the curve (AUC) of 0.97 (0.95–1.00) for schizophrenia detection. Finally, we tested its predictive performance for identifying patients before onset of psychosis using two cohorts of 445 pre-onset or at-risk individuals. The predictive performance achieved by the panel was excellent for identifying USA military personnel (AUC: 0.90 (0.86–0.95)) and help-seeking prodromal individuals (AUC: 0.82 (0.71–0.93)) who developed schizophrenia up to 2 years after baseline sampling. The performance increased further using the latter cohort following the incorporation of CAARMS (Comprehensive Assessment of At-Risk Mental State) positive subscale symptom scores into the model (AUC: 0.90 (0.82–0.98)). The current findings may represent the first successful step towards a test that could address the clinical need for early intervention in psychiatry. Further developments of a combined molecular/symptom-based test will aid clinicians in the identification of vulnerable patients early in the disease process, allowing more effective therapeutic intervention before overt disease onset.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/tp.2015.91

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 155

Metadata

Authors
Chan, M. K., Krebs, M.-O., Cox, D., Guest, P. C., Yolken, R. H., Rahmoune, H., Rothermundt, M., Steiner, J., Leweke, F. M., van Beveren, N. J. M., Niebuhr, D. W., Weber, N. S., Cowan, D. N., Suarez-Pinilla, P., Crespo-Facorro, B., Mam-Lam-Fook, C., Bourgin, J., Wenstrup, R. J., Kaldate, R. R., Cooper, J. D., & Bahn, S.
Venue
Translational Psychiatry
Published
2015-07-14
Volume
5
Issue
7
Pages
e601-e601
ISSN
2158-3188 (ISSN-L)
OpenAlex
W890438156
Cited by
155
References
9
FWCI
14.23
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset. https://app.cochat.ai/papers/10.1038/tp.2015.91
The paper
Chan, M. K., Krebs, M.-O., Cox, D., Guest, P. C., Yolken, R. H., Rahmoune, H., Rothermundt, M., Steiner, J., Leweke, F. M., van Beveren, N. J. M., Niebuhr, D. W., Weber, N. S., Cowan, D. N., Suarez-Pinilla, P., Crespo-Facorro, B., Mam-Lam-Fook, C., Bourgin, J., Wenstrup, R. J., Kaldate, R. R., . . . Bahn, S. (2015). Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset. Translational Psychiatry. https://doi.org/10.1038/tp.2015.91

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.